-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Home-made new crown recombinant protein vaccine enters Phase III clinical trials in Pakistan
Recently, Pakistani media "Daily Times" reported that the recombinant protein COVID-19 vaccine "ZF2001" jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongkoma Biopharmaceutical Co.
, Ltd.
will enter the phase 3 clinical phase in Pakistan and is expected to be included in 1 Ten thousand participants, 30% of whom are senior citizens
.
Previously, the inactivated vaccine developed by Sinopharm Group and the adenovirus vector vaccine brought by Connaught had carried out Phase 3 clinical studies in Pakistan.
So far, the country has become the first country in the world to accept three new coronavirus vaccines developed by China
.
In early February, academician Gao Fu of the Chinese Center for Disease Control and Prevention and others published in bioRxiv the protective effect of ZF2001 on the new South African variant strain (501Y.
V2), showing that although the vaccinator's serum has a slight decrease in the neutralizing effect of the new South African variant, However, most of the neutralizing activity is still retained, indicating that the vaccine still has a protective effect on the new South African variant
.
